SpyGlass Pharma, Inc. SGP
—
27.07
(0.58)
(2.10%)
as of 25 Sep
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (51.34%) | — | — | — |
+4 more TTM periods Free account |
|
| (42.05%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(22.08%) | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.39) | 0.00 | — | 0.00 | |
Free Cash Flow |
(46.36) | (37.96) | — | (30.42) | |
Capital Expenditures |
(2.81) | (1.04) | — | (0.81) | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(9.33%) | (7.37%) | 0.00% | (96.11%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.85 | 0.00 | — | 0.00 | |
Depreciation/Fixed assets |
0.19 | 0.26 | 0.00 | 0.24 | |
Capex/Depreciation |
(3.02) | (1.46) | — | (1.61) | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
(1.30) | 0.00 | — | 0.00 | |
Capex per Share |
(0.08) | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates